Results 21 to 30 of about 59,932 (250)

Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study [PDF]

Infectious Diseases and Therapy, 2023
Introduction In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients. Here we report results
Samuel M. Brown, Morgan J. Katz, Adit A. Ginde, Kavita Juneja, Monica Ramchandani, Joshua T. Schiffer, Carlos Vaca, Robert L. Gottlieb, Yuan Tian, Emon Elboudwarej, Joshua A. Hill, Richard Gilson, Lauren Rodriguez, Charlotte Hedskog, Shuguang Chen, Jairo M. Montezuma-Rusca, Anu Osinusi, Roger Paredes   +17 more
doaj   +2 more sources

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Nature, 2020
Effective therapies to treat coronavirus disease 2019 (COVID-19) are urgently needed. While many investigational, approved, and repurposed drugs have been suggested as potential treatments, preclinical data from animal models can guide the search for ...
Brandi N Williamson, Friederike Feldmann, Benjamin Schwarz   +2 more
exaly   +2 more sources

Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis [PDF]

Journal of Investigative Medicine High Impact Case Reports, 2023
End-stage kidney disease (ESKD) has been shown to be correlated with an increased risk of COVID-19 infection and mortality. Remdesivir is an effective non-EUA U.S.
Ryan Geffin MD, Shazia Raheem PharmD, Lavannya M. Pandit MD, MS, Andrew S. Hunter PharmD, Michael W. Holliday MD, PhD, Aditya V. Rao, Maulin K. Shah MD   +6 more
doaj   +3 more sources

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Proceedings of the National Academy of Sciences of the United States of America, 2020
Significance Middle East Respiratory Syndrome, caused by the MERS coronavirus (MERS-CoV), continues to cause severe respiratory disease with a high case fatality rate.
Emmie de Wit, Friederike Feldmann, Jacqueline Cronin   +2 more
exaly   +2 more sources

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

MBio, 2018
Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved therapeutics are available. The CoV nsp14 exoribonuclease (ExoN) has complicated development of antiviral nucleosides due to its proofreading activity.
Rachel L Graham, Timothy P Sheahan, Xiaotao Lu   +2 more
exaly   +2 more sources

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Journal of Biological Chemistry, 2020
Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome–coronavirus 2 (CoV-2).
Egor P Tchesnokov, Joy Y Feng, Danielle P Porter   +2 more
exaly   +2 more sources

Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study [PDF]

Infectious Diseases and Therapy, 2023
Introduction Remdesivir is a registered treatment for hospitalised patients with COVID-19 that has moderate clinical effectiveness. Anecdotally, some patients’ respiratory insufficiency seemed to recover particularly rapidly after initiation of ...
Emiel Leegwater, Lisa Dol, Menno R. Benard, Eveline E. Roelofsen, Nathalie M. Delfos, Machteld van der Feltz, Femke P. N. Mollema, Liesbeth B. E. Bosma, Loes E. Visser, Thomas H. Ottens, Nathalie D. van Burgel, Sesmu M. Arbous, Lahssan H. El Bouazzaoui, Rachel Knevel, Rolf H. H. Groenwold, Mark G. J. de Boer, Leo G. Visser, Frits R. Rosendaal, Erik B. Wilms, Cees van Nieuwkoop   +19 more
doaj   +4 more sources

Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis [PDF]

Swiss Medical Weekly, 2023
AIMS OF THE STUDY: Remdesivir has shown benefits against COVID-19. However, it remains unclear whether, to what extent, and among whom remdesivir can reduce COVID-19-related mortality. We explored whether the treatment response to remdesivir differed by
Janne Estill, Plamenna Venkova-Marchevska, Huldrych F. Günthard, Sara Botero-Mesa, Amaury Thiabaud, Maroussia Roelens, Laure Vancauwenberghe, Lauro Damonti, Ulrich Heininger, Anne Iten, Peter W. Schreiber, Rami Sommerstein, Sarah Tschudin-Sutter, Nicolas Troillet, Danielle Vuichard-Gysin, Andreas Widmer, Torsten Hothorn, Olivia Keiser   +17 more
doaj   +5 more sources

Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms

Science Translational Medicine, 2022
The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
Laura J Stevens, Andrea J Pruijssers, Hery Lee   +2 more
exaly   +2 more sources

The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis [PDF]

Case Reports in Infectious Diseases, 2020
Remdesivir is a nucleoside analog prodrug with broad-spectrum antiviral activity, including against coronaviruses. This has prioritized the inclusion of remdesivir in coronavirus disease 2019 (COVID-19) clinical trials.
Vincent Peyko, Helena Ladd, Anthony Cutrona   +2 more
doaj   +2 more sources